Slides
Page 1
Investor & Analyst Meet 2026 Strengthen the core. Expand adjacencies. Compound shareholder value.Diagnostics trusted by Doctors and Patients alike Metropolis Healthcare Limited
Page 2
SAFE HARBOURSafe HarbourThis presentation has been prepared by Metropolis Healthcare Limited for information purposes only. It does not constitute a prospectus, offering circular or offering memorandum, and is not a recommendation regarding any securities of the Company. It may contain forward-looking statements based on the beliefs, opinions and expectations of the Company as on the date of this presentation. These do not guarantee future performance and involve risks and uncertainties that are difficult to predict, including changes in economic, business, competitive, technological and regulatory conditions. The Company undertakes no obligation to publicly revise any forward-looking statement, except as required under applicable law. This presentation contains three-year directional ambitions expressed as ratios and revenue mix. They assume mid-teen volume-led revenue growth, no scheduled price increase, convergence of acquired businesses to company-level margins, delivery of the laboratory transformation and automation programme, continued improvement in centre productivity, and no material adverse change in the regulatory, competitive, tariff or reimbursement environment. Actual outcomes may differ materially. 2
Page 3
METROPOLIS AT A GLANCEA strong national network and legacy built over 45 years 209 / 5,000Laboratories andcollection centres750Towns in India, plusfive international markets₹1,646 CrFY26 revenue across B2C and B2B Revenue mix by geography, % · map not to scale 30,000 prescribing specialists, and every leading hospital chain is a client. B2C is 57% of revenue, through own and franchisee networks. B2B keeps the labs full: hospitals, labs and corporates send steady volume. Clinician trust and quality are the moat By Region West 50%South 27%North 18%East 5% 3
Page 4
MARKET CONTEXTMajority market is unorganised - and three shifts broadening it The shift to organised players is real, but gradual. $11 28.5 BnIndian diagnostics market to 2034, at 11% CAGR60%Of mortality from non-communicable disease 01 · SHIFT TO ORGANISED CARE●Expectations on accuracy, consistency and service are rising●Share moves to quality-led providers 02 · HEALTHCARE BEYOND METROS●New hospital capacity and Tier 2/3 access●More high-end testing outsourced 03 · ADVANCING TREATMENT PATHWAYS●Targeted therapies and biologics●Molecular, genomic and immunological testing expand 48% 15% 37% Unorganised / standaloneOr ganise d cha insHospital-based labs 4